Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 1:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Respiratory Patients Clear all
Completed Phase 3 Interventional

Effect of Tiotropium (Spiriva) on Exercise Tolerance in COPD Patients

NCT00274508
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium bromide
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 75 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
4
States / cities
Boston, Massachusetts • Rochester, Minnesota • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Sep 26, 2026, 1:23 AM EDT
Completed Phase 2 Interventional Results available

AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients

NCT00890825
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
AZD6244, docetaxel, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
4
States / cities
Los Angeles, California • Aurora, Colorado • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Sep 26, 2026, 1:23 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2a Study to Assess Safety, Daily Symptoms, PK, and Biomarkers of YPL-001 in COPD Patients

NCT02272634
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
YPL-001 80 mg, YPL-001 160 mg, Placebo
Drug
Lead sponsor
Yungjin Pharm. Co., Ltd.
Industry
Eligibility
30 Years to 85 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
4
States / cities
Birmingham, Alabama • Winter Park, Florida • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Sep 26, 2026, 1:23 AM EDT
Completed Phase 2 Interventional Results available

Gemcitabine and Carboplatin With or Without AZD2171 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00326599
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, cediranib maleate, gemcitabine hydrochloride
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
154
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Aurora, Illinois + 95 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Sep 26, 2026, 1:23 AM EDT
Completed Phase 3 Interventional Results available

Phase III Study of Idebenone in Duchenne Muscular Dystrophy (DMD)

NCT01027884
View directory record Official record
Conditions
Muscular Dystrophy, Duchenne, Ambulatory Care
Interventions
Placebo, Idebenone
Drug
Lead sponsor
Santhera Pharmaceuticals
Industry
Eligibility
10 Years to 18 Years · Male only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
9
States / cities
Sacramento, California • Aurora, Colorado • Gainesville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2015 · Synced Sep 26, 2026, 1:23 AM EDT
Recruiting Phase 3 Interventional

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

NCT06881784
View directory record Official record
Conditions
NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma), NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions
daraxonrasib, docetaxel
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
43
States / cities
Birmingham, Alabama • Long Beach, California • New Haven, Connecticut + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 26, 2026, 1:23 AM EDT
Completed Phase 2 Interventional Results available

A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor

NCT01853878
View directory record Official record
Conditions
Lung Cancer, Non-Small Cell
Interventions
Recombinant PRAME protein combined with the AS15 Adjuvant System GSK2302032A, Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
8
States / cities
Newark, Delaware • Springfield, Illinois • Rochester, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 26, 2026, 1:23 AM EDT
Completed Phase 2 Interventional Results available

OSI-774 in African American Patients With Advanced and Previously Treated Non-Small Cell Lung Cancer

NCT00230126
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
erlotinib
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 25, 2017 · Synced Sep 26, 2026, 1:23 AM EDT
Completed Phase 3 Interventional Results available

A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Rate Cycle Ergometry Test in COPD

NCT01525615
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Respimat inhaler, tiotropium+olodaterol (low dose), tiotropium + olodaterol (high dose), placebo to tiotropium+olodaterol
Device · Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 75 Years
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
15
States / cities
Torrance, California • Hartford, Connecticut • Springfield, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2016 · Synced Sep 26, 2026, 1:23 AM EDT
Withdrawn Phase 4 Interventional

Spironolactone to Improve Apnea and Cardiovascular Markers in Obstructive Sleep Apnea Patients

NCT04205136
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Spironolactone, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Sep 26, 2026, 1:23 AM EDT
Recruiting Not applicable Interventional

Exercise Training for the Improvement of Immune Activity and Treatment Outcomes During Immunotherapy for Non-small Cell Lung Cancer, BOOST Trial

NCT06983899
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma
Interventions
Aerobic Exercise, Exercise Intervention, Educational Intervention, Dual X-ray Absorptiometry, Electronic Health Record Review, Cardiopulmonary Exercise Testing, Physical Performance Testing, Questionnaire Administration, Biospecimen Collection, Pulmonary Function Test
Other · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 26, 2026, 1:23 AM EDT
Completed Phase 3 Interventional Results available

Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients

NCT04401293
View directory record Official record
Conditions
Sars-CoV2, COVID
Interventions
Enoxaparin, Prophylactic/Intermediate Dose Enoxaparin
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
6
States / cities
Newark, New Jersey • Bay Shore, New York • Huntington, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2021 · Synced Sep 26, 2026, 1:23 AM EDT
Completed Not applicable Interventional Results available

HVNI Ambulation Feasibility Study

NCT03885726
View directory record Official record
Conditions
Respiratory Insufficiency, Dyspnea
Interventions
Precision Flow Plus, Treatment as Usual
Device
Lead sponsor
Vapotherm, Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Saint Charles, Missouri • Mount Vernon, Ohio • Newport News, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Sep 26, 2026, 1:23 AM EDT
Completed Phase 2 Interventional Results available

18F-FSPG PET/CT in Diagnosing Early Lung Cancer in Patients With Lung Nodules

NCT03824535
View directory record Official record
Conditions
Cigarette Smoker, Current Smoker, Former Smoker, Multiple Pulmonary Nodules, Pulmonary Nodule
Interventions
Computed Tomography, Fludeoxyglucose F-18, Fluorine F 18 L-glutamate Derivative BAY94-9392, Positron Emission Tomography (PET/CT)
Diagnostic Test · Drug
Lead sponsor
Andrei Iagaru
Other
Eligibility
45 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Sep 26, 2026, 1:23 AM EDT
Terminated Phase 2 Interventional Results available

Long-term Safety Study of QGE031 in Patients With Allergic Asthma Who Completed Study CQGE031B2201

NCT02075008
View directory record Official record
Conditions
Asthma
Interventions
QGE031
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 76 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
5
States / cities
Evansville, Indiana • Owensboro, Kentucky • Waldorf, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Sep 26, 2026, 1:23 AM EDT
Completed Not applicable Interventional Results available

Improving the Sleep and Circadian Rhythms of Mechanically Ventilated Patients

NCT01284140
View directory record Official record
Conditions
Critical Illness, Sleep Deprivation, Respiratory Failure, Sleep Disorders, Circadian Rhythm
Interventions
Sleep and circadian rhythm promotion, Usual care
Behavioral
Lead sponsor
Brian Gehlbach
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Chicago, Illinois • Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 6, 2018 · Synced Sep 26, 2026, 1:23 AM EDT
Completed Phase 2 Interventional Results available

A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck

NCT01059643
View directory record Official record
Conditions
Ovarian Cancer, Non Small Cell Lung Cancer, Prostate Cancer, Colorectal Cancer, Gastric Cancer, Esophageal Cancer, Cancer of Head and Neck
Interventions
LY2523355, pegfilgrastim
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
18
States / cities
Jonesboro, Arkansas • Jacksonville, Florida • Macon, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Sep 26, 2026, 1:23 AM EDT
Completed Not applicable Interventional

Music Therapy to Address Patients' Journeys With Chronic Illness, Outcomes, and Readmission

NCT06214325
View directory record Official record
Conditions
Heart Failure, Chronic Obstructive Pulmonary Disease
Interventions
Music Therapy
Behavioral
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
40 Years to 89 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Sep 26, 2026, 1:23 AM EDT
Completed No phase listed Observational

Photodynamic Therapy Using Porfimer Sodium in Treating Patients With Non-Small Cell Lung Cancer And Bronchial Disease

NCT00754910
View directory record Official record
Conditions
Lung Cancer
Interventions
porfimer sodium, bronchoscopy
Drug · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced Sep 26, 2026, 1:23 AM EDT
Completed Phase 2 Interventional

S9712: Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage III Non-small Cell Lung Cancer

NCT00003158
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, etoposide, paclitaxel, radiation therapy
Drug · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2007
U.S. locations
86
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2012 · Synced Sep 26, 2026, 1:23 AM EDT
Terminated Not applicable Interventional Results available

Use of Dexmedetomidine to Facilitate Extubation in Surgical ICU Patients Who Failed Previous Weaning Attempts

NCT00464490
View directory record Official record
Conditions
Intubation; Difficult, Respiration Disorders
Interventions
Dexmedetomidine
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 69 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2014 · Synced Sep 26, 2026, 1:23 AM EDT
Completed Phase 3 Interventional Results available

Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With Lung Cancer

NCT02272413
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
BI 695502, Avastin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
671 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
9
States / cities
Anaheim, California • Bakersfield, California • Fountain Valley, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Sep 26, 2026, 1:23 AM EDT
Not listed No phase listed Observational

Prospective Observational Study to Evaluate Biomarkers of Aminoglycoside Nephrotoxicity in Patients With Cystic Fibrosis

NCT01543620
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Foundation for the National Institutes of Health
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
3
States / cities
Los Angeles, California • Minneapolis, Minnesota • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 8, 2014 · Synced Sep 26, 2026, 1:23 AM EDT
Terminated Phase 2 Interventional Results available

Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer

NCT03050060
View directory record Official record
Conditions
Metastatic Kidney Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Renal Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
Atezolizumab, Hypofractionated Radiation Therapy, Laboratory Biomarker Analysis, Nelfinavir Mesylate, Nivolumab, Pembrolizumab
Drug · Radiation · Other + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Sep 26, 2026, 1:23 AM EDT